Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans | ||||||||||||
By: PR Newswire Association LLC. - 28 Sep 2017 | Back to overview list |
|||||||||||
LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") routinely evaluates refinancing opportunities, including capital markets transactions, to continue to enhance its capital structure. As part of this, the Company filed a routine private placement exemption application with Autorité des marchés financiers, the principal securities regulator in Quebec. At this time, no decision has been made with respect to any capital markets transactions. The Company does not intend to provide any updates on its financing plans until a definitive decision on any such financing has been made. About Valeant Forward-looking Statements
View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-provides-update-on-canadian-regulatory-filing-about-future-financing-plans-300527239.html SOURCE Valeant Pharmaceuticals International, Inc. |
||||||||||||
|
||||||||||||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |